<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781092</url>
  </required_header>
  <id_info>
    <org_study_id>SUSE-01</org_study_id>
    <nct_id>NCT00781092</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes</brief_title>
  <official_title>A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durrie Vision</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Durrie Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare two post operative drop regimens for the&#xD;
      management of dry eye and control of healing using FDA-approved ophthalmic solutions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This comparison will be made between bilateral eyes of the same patient following excimer&#xD;
      laser ablation using the FDA-approved LADARVision 4000 Excimer Laser System or the WaveLight&#xD;
      ALLEGRETTO WAVEâ„¢ Excimer Laser System. Post operative questionnaires regarding the use of the&#xD;
      drops will be compared. Tear osmolarity and tear breakup time will be evaluated using Tear&#xD;
      Lab and OQAS II.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear osmolarity</measure>
    <time_frame>2 week, 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tear Break Up Time</measure>
    <time_frame>2 week, 1 month post op</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systane Ultra</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bausch and Lomb Sensitive Eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Systane Ultra</intervention_name>
    <description>Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Natural Tears</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bausch and Lomb Sensitive Eyes</intervention_name>
    <description>Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Saline Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be a suitable candidate for FDA Approved LASIK.&#xD;
&#xD;
          -  Subjects must have a stable refraction as documented by previous clinical records.&#xD;
&#xD;
          -  Subjects who wear soft contact lenses must discontinue wear at least 3 days prior to&#xD;
             preoperative exam or surgery.&#xD;
&#xD;
          -  Subjects who wear gas permeable contact lenses must discontinue wear at least 3 weeks&#xD;
             prior to preoperative exam or surgery.&#xD;
&#xD;
          -  Subjects must be at least 18 years of age.&#xD;
&#xD;
          -  Subjects must be willing and able to return for scheduled follow up examinations each&#xD;
             day after surgery at the specified time.&#xD;
&#xD;
          -  Subjects must sign and be given a copy of the written Informed Consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects for whom either eyes do not meet all inclusion criteria and either eye meets&#xD;
             any exclusion criteria.&#xD;
&#xD;
          -  Subjects with clinically significant dry eye syndrome or clinically significant&#xD;
             blepharitis in either eye.&#xD;
&#xD;
          -  Subjects with clinically significant anterior segment pathology, including clinically&#xD;
             significant cataracts, corneal scarring or neovascularization in either eye.&#xD;
&#xD;
          -  Subjects who have undergone previous intraocular or corneal surgery of any kind,&#xD;
             including any type of surgery for either refractive or therapeutic purposes in either&#xD;
             eye.&#xD;
&#xD;
          -  Subjects who have a history of Herpes zoster or Herpes simplex keratitis.&#xD;
&#xD;
          -  Subjects on chronic systemic corticosteroid or other immunosuppressive therapy that&#xD;
             may affect wound healing, any immunocompromised subjects, and subjects with clinically&#xD;
             significant atopic disease, connective tissue disease, or uncontrolled diabetes.&#xD;
&#xD;
          -  Subjects with a history of steroid-responsive rise in intraocular pressure, glaucoma,&#xD;
             or preoperative IOP&gt;25 mm Hg in either eye.&#xD;
&#xD;
          -  Subjects with macular pathology in either eye.&#xD;
&#xD;
          -  Subjects who are pregnant, lactating, or planning to be pregnant during the course of&#xD;
             the study.&#xD;
&#xD;
          -  Subjects with known sensitivity to planned study concomitant medications.&#xD;
&#xD;
          -  Subjects participating in any other ophthalmic drug or device clinical trial during&#xD;
             the time of this clinical investigation.&#xD;
&#xD;
          -  Use of ocular drugs, other than study medications, during the study and within 30 days&#xD;
             prior to study entry or any other ocular medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel S. Durrie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Durrie Vision</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.durrievision.com/index.cfm/research</url>
    <description>Durrie Vision Research</description>
  </link>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>October 27, 2008</study_first_submitted>
  <study_first_submitted_qc>October 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2008</study_first_posted>
  <last_update_submitted>September 19, 2012</last_update_submitted>
  <last_update_submitted_qc>September 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Durrie Vision</investigator_affiliation>
    <investigator_full_name>Daniel S. Durrie, MD</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>Dry Eyes</keyword>
  <keyword>LASIK</keyword>
  <keyword>Laser Vision Correction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

